Endocrine Abstracts

JOINT1345

Adrenocortical carcinoma (ACC) is a rare but aggressive malignancy, with a poor overall survival. It can present itself in different ways, but most of the patients display symptoms of hormonal excess. Mitotane is a treatment option as an adjuvant therapy after surgery or for unresectable/advanced ACC, also combined in a platinum-based therapy. It is an adrenolytic drug that affects adrenal steroidogenesis and interferes with mitochondrial function reducing cell viability. Other therapeutics are used to relieve the symptoms of ACC with hypercortisolism, such as metyrapone and osilodrostat, both steroidogenesis inhibitors. Specifically, osilodrostat is a drug that inhibits adrenal 11β-hydroxylase and blocks aldosterone synthase, which are enzymes acting in the final step of cortisol and aldosterone synthesis. The main objective of this research consists of the comparison of effects of mitotane, metyrapone and osilodrostat on adrenocortical carcinoma cell lines, such as SW-13 and NCI-H295R: the first is a non-secreting cell line, the second is a glucocorticoids-, mineralocorticoids-, and adrenal androgen-secreting line, often used as a model in experiments on human steroidogenesis. While the effects of metyrapone and osilodrostat on ACC hypercortisolism have been proven in the last few years, there is no specific data about their effects on tumoral cells viability and how they can influence them. In this view, a study involving both cell lines could be an effective method to assess valuable information from an in vitro model. Both for SW-13 and NCI-H295R cells, the experiments were performed with 2D cultures and then 3D models (e.g. spheroids) to reproduce the complex structure of an in vivo environment. The cultures were treated with different concentrations of mitotane, metyrapone and osilodrostat. Moreover, a combination of mitotane and osilodrostat and of mitotane and metyrapone were tested on ACC cell cultures. 2D models were cultured in DMEM-F12 medium supplemented with 10% of fetal bovine serum (SW13 cells) or with DMEM-F12 medium supplemented with 2.5% of Nu-Serum and ITS+ Premix supplement (NCI-H295R). Cell viability was assessed with MTS assay. 3D models were obtained using specific microwell plates to be evaluated via a physical cytometer establishing information about spheroids features and indirectly to cell death extent. Although the study is currently in a preliminary phase, we evaluated changes in cell viability and in steroidogenesis in 2D models. The next step will consist of a deeper characterization and evaluation of 3D models.